Investment
Features
FeesSafety
Academy
More
Pluang+

Orchestra BioMed aims to complete BACKBEAT trial enrollment by Q3 2026, with data presentation in Q2 2027.

Market News
12 May 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Orchestra BioMed, in collaboration with Medtronic, targets finishing enrollment for the BACKBEAT trial by the end of Q3 2026. This trial evaluates AVIM Therapy, a pacemaker-based treatment for uncontrolled hypertension. They plan to present primary endpoint results at a major cardiology conference in Q2 2027 and, if successful, Medtronic will seek FDA approval and global regulatory clearances. The trial's sample size was reduced with FDA approval but remains statistically robust to assess safety and efficacy at 3 months.

More News (MDT)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App